GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Basic Sciences/Pancreatic Acinus and Pancreatic Stellate Cells

Pancreatic Acinus and Pancreatic Stellate Cells

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated April 1, 2025

Quick Answer

Pancreatic Acinus and Pancreatic Stellate Cells are important components of the pancreas, which is a gland located in the abdomen. Here's a detailed explanation of both: ### **Pancreatic Acinus:** 1.


Pancreatic Acinus and Pancreatic Stellate Cells are important components of the pancreas, which is a gland located in the abdomen. Here's a detailed explanation of both:

### **Pancreatic Acinus:**

1. **Definition:** Pancreatic acini are small clusters of cells in the pancreas responsible for producing and secreting digestive enzymes. These enzymes help in breaking down food in the small intestine.

2. **Structure:** Acini are made up of acinar cells, which are pyramid-shaped cells. These cells surround a small central duct, forming a grape-like structure. The central duct drains the enzymes produced by acinar cells.

3. **Function:**

  • Acinar cells synthesize and secrete enzymes such as amylase (for carbohydrate digestion), lipase (for fat digestion), and proteases (for protein digestion).
  • These enzymes are released into the pancreatic ducts and eventually reach the small intestine to aid digestion.
  • Acinar cells also produce inactive enzyme precursors (zymogens) to prevent damage to the pancreas itself. These precursors become active in the intestine.

4. **Regulation:** Hormones like **cholecystokinin (CCK)** and **secretin** regulate the activity of acinar cells. CCK stimulates enzyme secretion, while secretin promotes the release of bicarbonate to neutralize stomach acid.

---

### **Pancreatic Stellate Cells (PSCs):**

1. **Definition:** Pancreatic stellate cells are specialized cells located in the pancreas that play a role in maintaining the organ's structure and responding to injury or inflammation.

2. **Structure:** These cells have a star-shaped appearance (hence the name "stellate"). They are found in the connective tissue around the acini and ducts.

3. **Function:**

  • **Normal State:** In a healthy pancreas, PSCs are inactive and help maintain the extracellular matrix (the supporting structure of the pancreas).
  • **Activated State:** When the pancreas is injured or inflamed (e.g., in pancreatitis or pancreatic cancer), PSCs become activated. In this state, they produce collagen and other substances that lead to fibrosis (scarring).
  • PSCs are involved in repairing damage but excessive activation can lead to fibrosis, which disrupts normal pancreatic function.

4. **Role in Disease:**

  • In chronic pancreatitis and pancreatic cancer, PSCs contribute to the development of fibrosis, making these conditions worse.
  • They are a focus of research for developing therapies to prevent or reduce fibrosis in pancreatic diseases.

---

### **Key Differences Between Pancreatic Acinus and Stellate Cells:**

| **Feature** | **Pancreatic Acinus** | **Pancreatic Stellate Cells** |

|-------------------------------|--------------------------------------------|---------------------------------------------|

| **Location** | Found in clusters (acini) around ducts | Found in connective tissue around acini |

| **Function** | Produces digestive enzymes | Maintains extracellular matrix, responds to injury |

| **Role in Disease** | Dysfunction leads to reduced enzyme production (e.g., exocrine insufficiency) | Excessive activation leads to fibrosis in pancreatic diseases |

---

### **Clinical Significance:**

1. **Pancreatic Acinus:** Dysfunction in acinar cells can lead to conditions like exocrine pancreatic insufficiency, where the pancreas fails to produce enough digestive enzymes. This results in malabsorption and digestive problems.

2. **Pancreatic Stellate Cells:** Overactivation of PSCs is linked to chronic pancreatitis and pancreatic cancer. Research is ongoing to find ways to inhibit PSC activation and reduce fibrosis.

Understanding the roles of these cells is crucial for diagnosing and treating pancreatic diseases effectively.

Related Q&A

ARID1A Loss Drives ICC Development: Hepatology | June 2026

Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...

Blocking Succinate–GPR91 Signaling in MASH: Hepatology | April 2026

Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...

THRSP–MIF Signaling Drives MASH Progression: Hepatology | April 2026

Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...

Butyrate and Butyrate-Producing Bacteria in CKM: Antioxidants | July 2026

Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...

CK7, CK20, and CDX2 Refine Prognosis in Small Intestinal Adenocarcinoma: Annals of Oncology | 2026

• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...

Fatty Liver Drives Hyperglycemia Through Liver–Gut Signaling : Cell Metab | Jun 2026

Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer